This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Public Health  • World Health  • Alert me on articles by topic

Jon L. Yang, MPH; Thomas M. Lietman, MD

Arch Ophthalmol. 2007;125(7):989-991.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

JAMA

Impact of Annual Targeted Treatment on Infectious Trachoma and Susceptibility to Reinfection: 

Berna Atik, MD, MPH; Ton Ton Kim Thanh, MD; Vu Quoc Luong, MD; Stephane Lagree, PhD; Deborah Dean, MD, MPH

Context: The World Health Organization developed the SAFE strategy (Surgery for trichiasis; Antibiotics for Chlamydia trachomatis infection; Facial cleanliness; and Environmental improvement) to eliminate blinding trachoma globally by the year 2020. Despite a number of studies using various intervals of treatment for different prevalence rates, there has been a lack of sufficient follow-up beyond the final treatment point to determine rates of recurrence of disease and infection and the risk factors that may contribute to each.

Objective: To evaluate the impact of 2 annual targeted azithromycin treatments on active trachoma and C trachomatis infection rates over 3 years in Vietnam.

Design, Setting, and Participants: Three communes were randomly selected . . . [Full Text of this Article]